|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||81.25 - 82.46|
|52 Week Range||24.55 - 92.97|
|PE Ratio (TTM)||11.49|
|Dividend & Yield||3.30 (3.40%)|
|1y Target Est||N/A|
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.
Dupixent combined with standard of care also showed 12%–15% improvement in FEV1 from baseline in asthma patients after 12 weeks of treatment compared to those treated with standard of care alone.
As a treatment option for adult AD patients eligible for systemic therapy, Dupixent is expected to be approved in the European Union in 3Q17.